Zelasudil
AssetAlso RXC007
Selective ROCK2 inhibitor
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 5
- Indications
- 2
- Trials
- 1
- Developer
Indications
5Fibrosis
Phase 2, Active not recruiting, NCT05570058, clinicaltrials.gov, 7 Oct 2026
Idiopathic pulmonary fibrosis
Phase 2, Active not recruiting, NCT05570058, clinicaltrials.gov, 7 Oct 2026
Kidney disease
Phase 1, Completed, NCT04931147, clinicaltrials.gov, 7 Oct 2026
2 more
In the full profile
- Targets and what it contains3
- Owner and partners2
- Trials2
- Evidence for its targets1
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 3 sources